Insmed Inc. (INSM) announced Monday morning that the FDA has lifted the clinical hold previously placed on ARIKACE in Cystic Fibrosis patients with Pseudomonas lung infections.
Insmed gapped up sharply Monday and rose steadily until mid-morning. The stock ended the session higher by 1.40 at $4.10, with volume at a 3 1/2 month high. Insmed jumped to nearly a 2-month high and re-crossed its 50-day moving average.
For comments and feedback: editorial@rttnews.com